Dark

REGN
Regeneron Pharmaceuticals Inc
stock NASDAQ

At Close

Feb 24, 2026 3:59:55 PM EST

771.93USD-1.920%(-15.11)628,622

0.00Bid 0.00Ask 0.00Spread

Pre-market

0.00USD-100.000%(-787.04)0

After-hours

Feb 24, 2026 4:00:30 PM EST

772.19USD+0.034%(+0.26)14,385

OverviewOptionsHistoricalExchangesShortsNews

Jan 31, 2022

09:18AM EST Analyst Ratings For Regeneron Pharmaceuticals Benzinga

08:42AM EST Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $754 Benzinga

06:45AM EST CHMP Backs Sanofi-Regeneron's Dupixent For Asthma Patients Aged 6 - 11 Years With Type 2 Inflammation Benzinga

05:47AM EST European Medicines Agency's Committee for Medicinal Products for Human Use Recommended Approval of Dupixent for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation Benzinga

01:29AM EST Sanofi: CHMP Recommends Approval Of Dupixent For Children RTTNews

01:02AM EST Sanofi :CHMP Recommends Approval Of Dupixent For Children Aged 6 To 11 Yrs With Severe Asthma With Type 2 Inflammation RTTNews

12:59AM EST CHMP Recommends Approval of Dupixent(r) (dupilumab) for Children Aged 6 to 11 PR Newswire

Jan 28, 2022

10:32AM EST Regeneron, Sanofi Withdraw FDA Application For Libtayo's Expanded Use Benzinga

08:21AM EST The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron Benzinga

07:41AM EST Regeneron Pharmaceuticals, Inc. (REGN), and French drug maker Sanofi, said Friday that they voluntarily withdrew the supplemental Biologics License Application or sBLA, filed for Libtayo or Cemiplimab-rwlc, as a second-line treatment for advanced cervical cancer. RTTNews

07:03AM EST Regeneron And Sanofi Provide Regulatory Update On Libtayo In Advanced Cervical Cancer Benzinga

07:03AM EST Regeneron And Sanofi Announce Voluntary Withdrawal Of SBLA For Libtayo In Advanced Cervical Cancer RTTNews

07:00AM EST Regeneron and Sanofi Provide Regulatory Update on Libtayo(r) (cemiplimab-rwlc) PR Newswire

Jan 25, 2022

05:34AM EST A Peek Into The Markets: US Stock Futures Mostly Lower Ahead Of Earnings, Fed Meeting Benzinga

Jan 24, 2022

10:28PM EST FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why Benzinga

02:17PM EST Analysis: Why Is It So Difficult To Obtain COVID-19 Monoclonal Antibody Treatments? Benzinga

Jan 20, 2022

12:01PM EST Forty Accomplished Young Scientists Named Finalists in the 2022 Regeneron PR Newswire

Jan 19, 2022

09:29AM EST Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease Benzinga

07:40AM EST The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data Benzinga

07:28AM EST Regeneron Pharmaceuticals Inc. (REGN) said Wednesday that the U.S. Food and Drug Administration has accepted for review the supplemental Biologics License Application (sBLA) for PD-1 inhibitor Libtayo (cemiplimab-rwlc) in combination with chemotherapy as first-line treatment in advanced non-small cell lung cancer or NSCLC. RTTNews

07:03AM EST Regeneron Announces FDA Accepts For Review Libtayo In Combination With Chemotherapy For First-Line Treatment Of Advanced NSCLC Benzinga

07:03AM EST Regeneron: FDA Accepts For Review Libtayo In Combination With Chemotherapy For 1st-line Treatment Of Advanced NSCLC RTTNews

07:01AM EST FDA Accepts for Review Libtayo(r) (cemiplimab-rwlc) in Combination with PR Newswire

01:34AM EST Sanofi Says Second Phase 3 Dupixent Trial Confirms RTTNews

01:02AM EST Regeneron And Sanofi Say Phase 3 Dupixent Trial Confirms Significant Improvements For Patients With Prurigo Nodularis RTTNews

12:59AM EST Second Positive Phase 3 Dupixent(r) (dupilumab) Trial Confirms Significant PR Newswire

Jan 18, 2022

10:39AM EST Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Lowers Price Target to $585 Benzinga

Jan 14, 2022

12:22PM EST WHO Recommends Glaxo, Eli Lilly Drugs For COVID-19 Treatment Amid Omicron Surge Benzinga

Jan 13, 2022

04:05PM EST Regeneron to Report Fourth Quarter and Full Year 2021 Financial and Operating PR Newswire

12:55PM EST Connect Biopharma's Latest Dermatitis Drug Update Fails to Pump Up Shares Benzinga

Jan 10, 2022

06:19AM EST Regeneron Pharmaceuticals Announces FDA No Longer Plans To Convene An Advisory Committee To Discuss REGEN-COV BLA For Treatment And Prophylaxis Benzinga

06:18AM EST Regeneron Pharmaceuticals Sees Prelim U.S. Net Product Sales Of REGEN-COV Of ~$5.82B For FY21; Sees Prelim U.S. Net Product Sales Of EYLEA Injection Of ~$5.79B For FY21 Benzinga

Jan 7, 2022

01:02PM EST Regeneron, Ultragenxy Report Collab to Commercialize Evkeeza Outside US Benzinga

08:26AM EST Regeneron Pharmaceuticals Inc. (REGN) and Ultragenyx Pharmaceutical Inc., on Friday, announced a license and collaboration deal to clinically develop, commercialize, and distribute Evkeeza in countries outside of the U.S. RTTNews

07:01AM EST Regeneron And Ultragenyx Collaborate To Commercialize Evkeeza Outside The U.S. RTTNews

07:01AM EST Regeneron and Ultragenyx Collaborate to Commercialize Evkeeza(r) (evinacumab) PR Newswire

Jan 5, 2022

12:18PM EST Why This Pfizer, Regeneron Analyst Has Contrasting Recommendations For The COVID Stock Plays Benzinga

10:09AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2022 Benzinga

07:14AM EST B of A Securities Downgrades Regeneron Pharmaceuticals to Underperform, Lowers Price Target to $575 Benzinga

Jan 3, 2022

06:18AM EST Bernstein Upgrades Regeneron Pharmaceuticals to Outperform, Announces $660 Price Target Benzinga

Dec 22, 2021

04:15PM EST Regeneron Announces Presentation at the 40th Annual J.P. Morgan Healthcare PR Newswire

03:46PM EST White House Covid-19 Response Coordinator Zients Says Anti-viral Treatments Will Be Provided to States, Localities at No Charge Benzinga

07:37AM EST Alnylam Pharmaceuticals, Inc. (ALNY) has submitted a Clinical Trial Authorization application to The Medicines and Healthcare Products Regulatory Agency in the United Kingdom to begin a phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein for the treatment of Alzheimer's disease and cerebral amyloid angiopathy. RTTNews

Dec 16, 2021

01:27PM EST AstraZeneca's COVID-19 Antibody Effective Against Omicron Variant Benzinga

07:44AM EST Regeneron CEO Says Developing New Antibodies Benzinga

07:43AM EST Regeneron CEO Says Delta Is Still Surging, Cocktail Effective Benzinga

Dec 15, 2021

10:05AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021 Benzinga

06:14AM EST Bernstein Downgrades Regeneron Pharmaceuticals to Market Perform, Announces $660 Price Target Benzinga

Dec 13, 2021

01:03PM EST Regeneron, Sanofi Early Monday Announced Phase 3 Dupixent Data In Children 6 Months To 5 Years For Moderate-To-Severe Atopic Dermatitis Showed Improvement In Skin Clearance, Reduced Disease Severity Benzinga

01:01PM EST Regeneron Early Monday Announced Phase 3 Dupixent Data In Children 6 Months To 5 Years For Moderate-To-Severe Atopic Dermatitis Showed Improvement In Skin Clearance, Reduced Disease Severity Benzinga

01:21AM EST Phase 3 results showed that adding Dupixent or dupilumab to standard-of-care topical corticosteroids significantly improved skin clearance and reduced overall disease severity and itch in infants and children aged 6 months to 5 years with uncontrolled moderate-to-severe atopic dermatitis, Regeneron Pharmaceuticals Inc. (REGN) and Sanofi said in a statement on Monday. RTTNews

01:04AM EST Regeneron : Phase 3 Results Show Dupixen Improved Skin Clearance In Children With Moderate-to-severe Atopic Dermatitis RTTNews

12:59AM EST with Moderate-to-severe Atopic Dermatitis Featured in RAD 2021 Late-breaking Session PR Newswire

Dec 11, 2021

12:55PM EST Regeneron Pharmaceuticals Inc. (REGN) said that results from the Phase 1 portion of the Phase 1/2 trial in patients with relapsed/refractory multiple myeloma found a 51% overall response rate across all dose groups, rising to 75% in patients who received higher doses of REGN5458 (200-800 mg). RTTNews

12:24PM EST Regeneron Announced New REGN5458 (BCMAxCD3) Phase 1 Data Show 75% Response Rate at Highest Dose Levels Studied in Patients with Heavily Pretreated Multiple Myeloma at ASH 2021 Benzinga

12:08PM EST Regeneron : REGN5458 Phase 1 Data Show 75% Response Rate At Highest Dose Levels In Heavily Pretreated Multiple Myeloma RTTNews

12:00PM EST New REGN5458 (BCMAxCD3) Phase 1 Data Show 75% Response Rate at Highest Dose PR Newswire

Dec 9, 2021

09:52PM EST Novartis Reveals Two Year Results From Beovu Trial In Diabetic Macular Edema Patients Benzinga

09:50PM EST Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021 Benzinga

09:47PM EST Wells Fargo Initiates Coverage On Regeneron Pharmaceuticals with Overweight Rating, Announces Price Target of $750 Benzinga

Dec 8, 2021

05:29PM EST New England Journal of Medicine Publishes Positive Phase 3 Dupixent(r) PR Newswire

Dec 6, 2021

11:13AM EST Where Regeneron Pharmaceuticals Stands With Analysts Benzinga

10:05AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2021 Benzinga

07:10AM EST Goldman Sachs Initiates Coverage On Regeneron Pharmaceuticals with Buy Rating, Announces Price Target of $824 Benzinga

06:07AM EST The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More Benzinga

Dec 3, 2021

10:01AM EST Regeneron to Participate in H.C. Wainwright & Co. Virtual Event PR Newswire

Nov 30, 2021

04:49PM EST Regeneron CEO Says Data Is Going To Emerge Over Next Month On Effect Of Omicron Variant Benzinga

04:48PM EST Watching COVID-19 Antibody Drug Stocks; Wall Street Journal Earlier Reports 'Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates' Benzinga

04:47PM EST The Daily Biotech Pulse: Cumberland Jumps On FDA Nod, Regeneron Says Antibody Treatment May Be Less Effective Against Omicron, ImmunoGen Readout Benzinga

04:42PM EST Regeneron Says Its Covid-19 Antibody Drug Cocktail Has Less Effectiveness Against Omicron Variant; Says Further Testing Needed to Quantify Impact of New Variant Benzinga

Nov 23, 2021

01:58AM EST Nykode Therapeutics (VACC), a developer of vaccines and novel immunotherapies, said on Tuesday that it has signed a license and collaboration deal with a potential of over $925 million with Regeneron Pharmaceuticals (REGN), a biotechnology company, for the discovery, development, and commercialization of potential new vaccines for cancer and infectious diseases. RTTNews

01:16AM EST Nykode Enters Into Agreement With Regeneron To Develop Innovative Vaccines Against Cancer And Infectious Diseases RTTNews

Nov 22, 2021

10:34AM EST Regeneron Extends Hearing Loss Gene Therapy pact With Decibel Benzinga

Nov 19, 2021

08:20AM EST The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial Benzinga

Nov 16, 2021

04:15PM EST Regeneron Announces Investor Conference Presentations PR Newswire

Nov 15, 2021

10:47AM EST A Peek Into The Markets: US Stock Futures Higher Ahead Of Tyson Foods Earnings Benzinga

09:29AM EST Regeneron Announces $3B Share Repurchase Program Benzinga

07:01AM EST Regeneron Listed on Dow Jones Sustainability World Index for Third Consecutive PR Newswire

Nov 12, 2021

11:04PM EST Regeneron Pharmaceuticals Inc. (REGN) said Friday that European Commission has approved the casirivimab and imdevimab antibody cocktail, known as REGEN-COV in the U.S. and Ronapreve in the European Union and other countries. RTTNews

04:27PM EST Regeneron Announces $3 Bln Share Repurchase Program RTTNews

04:12PM EST Regeneron Announces $3 Billion Share Repurchase Program PR Newswire

01:13PM EST Europe Approves Regeneron - Roche's COVID-19 Antibody Cocktail Benzinga

10:26AM EST Regeneron Pharmaceuticals' Co-Developed Antibody Cocktail Approved By European Commission To Treat And Prevent COVID-19 Benzinga

10:20AM EST Regeneron Antibody Cocktail Approved by European Commission to Treat and PR Newswire

Nov 11, 2021

02:04PM EST EU Regulator Backs Regeneron-Roche's COVID-19 Drug Benzinga

11:05AM EST Regeneron Press Release Confirms EU Approval For Its Antibody Cocktail To Treat, Prevent COVID Benzinga

11:03AM EST CHMP Recommends EU Approval of Regeneron Antibody Cocktail to Treat and Prevent PR Newswire

10:12AM EST Regeneron Shares Quiet Following Headline EU Regulator Has Recommended Authorizing Roche/Regeneron COVID Drug Benzinga

Nov 10, 2021

11:05AM EST Booster and Renewable Energy Group Enter Strategic Partnership To Offer Mobile Delivery Of Sustainable Fuels Benzinga

Nov 9, 2021

10:47AM EST When Winning Streaks Stop: Trying To Beat The Market By Buying Stocks Like Tesla Benzinga

Nov 8, 2021

09:46AM EST Regeneron-Roche's COVID-19 Treatment Shows Long Term Benefit After Single Dose Benzinga

07:46AM EST Regeneron: REGEN-COV Show Long-term Protection Against RTTNews

07:03AM EST Regeneron Pharmaceuticals Says New Phase 3 Analyses Show That Single Dose Of REGEN-COV (casirivimab and imdevimab) Provides Long-Term Protection Against COVID-19 Benzinga

07:03AM EST Regeneron : Phase 3 Analyses Show Single Dose Of REGEN-COV Provides Long-term Protection Against COVID-19 RTTNews

07:01AM EST New Phase 3 Analyses Show That a Single Dose of REGEN-COV(r) (casirivimab and PR Newswire

Nov 5, 2021

01:24PM EDT Wall Street Crime and Punishment: Martin Shkreli, The Self-Destructive Pharma Bro Benzinga

12:12PM EDT What 8 Analyst Ratings Have To Say About Regeneron Pharmaceuticals Benzinga

10:55AM EDT SVB Leerink Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $850 Benzinga

10:39AM EDT Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $617 Benzinga

10:07AM EDT Benzinga's Top Ratings Upgrades, Downgrades For November 5, 2021 Benzinga

09:44AM EDT Benchmark Downgrades Regeneron Pharmaceuticals to Hold Benzinga

09:37AM EDT HC Wainwright & Co. Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $844 Benzinga

09:25AM EDT Regeneron Filing Shows Registration For Mixed Securities Shelf Offering Benzinga

Nov 4, 2021

11:33AM EDT Regeneron Pharmaceuticals Earnings Perspective: Return On Invested Capital Benzinga

10:03AM EDT Regeneron To Present Clinical Research Data On Blood Cancers And Disorders RTTNews

10:03AM EDT Regeneron Highlights Presentations At Upcoming American Society Of Hematology Dec. 11-13 Benzinga

10:01AM EDT Regeneron Presentations at ASH Highlight Expanding Clinical Research in Blood PR Newswire

09:46AM EDT Regeneron shares were trading higher after the company reported better-than-expected Q3 EPS and sales results. Benzinga

09:36AM EDT From Regeneron Conference Call Earlier: Sees Q4 Deliveries Of Its REGN-CoV In US ~800K Doses Benzinga

09:24AM EDT Why Regeneron Shares Are Rising Today Benzinga

08:19AM EDT The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO Benzinga

06:38AM EDT Regeneron Pharmaceuticals Sees FY21 Non-GAAP R&D $2.55B-$2.6B Benzinga

06:36AM EDT Regeneron Pharmaceuticals (REGN) released earnings for its third quarter that advanced from the same period last year. RTTNews

06:32AM EDT Regeneron Q3 Revenues Increase 51% To $3.45 Bln RTTNews

06:32AM EDT Regeneron Pharmaceuticals Q3 Adj. EPS $15.37 Beats $9.49 Estimate, Sales $3.45B Beat $2.79B Estimate Benzinga

06:31AM EDT Regeneron Reports Third Quarter 2021 Financial and Operating Results PR Newswire

05:00AM EDT Earnings Scheduled For November 4, 2021 Benzinga

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 29, 2021

08:00AM EDT The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs Benzinga

Oct 26, 2021

12:31PM EDT Where Regeneron Pharmaceuticals Stands With Analysts Benzinga

06:50AM EDT SVB Leerink Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $798 Benzinga

Oct 25, 2021

11:18AM EDT Regeneron Early Monday Morning Announced Phase 3 Results From Trial Assessing Investigational Use Of Co.'s Dupixent In Patients 12+ With Eosinophilic Esophagitis Benzinga

01:30AM EDT Regeneron Pharmaceuticals Inc. (REGN) and Sanofi (SNY) announced Monday positive results from the second Dupixent (dupilumab) Phase 3 Eosinophilic Esophagitis trial that showed significant disease improvements. Data from the clinical trial program will be submitted to regulatory authorities by 2022. RTTNews

01:04AM EDT Regeneron, Sanofi Announce Second Phase 3 Trial Of Dupixent Meets Co-primary Endpoints In Eosinophilic Esophagitis RTTNews

12:59AM EDT Demonstrate Significant Disease Improvements, Underscoring Role of Type 2 Inflammation in This Complex Disease PR Newswire

Oct 24, 2021

11:45AM EDT The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More Benzinga

Oct 22, 2021

12:41PM EDT HC Wainwright & Co. Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $842 Benzinga

07:36AM EDT The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs Benzinga

01:20AM EDT Regeneron Pharmaceuticals Inc. (REGN) and Sanofi said that phase 3 results from a trial, which evaluated Dupixent or dupilumab in adults with uncontrolled prurigo nodularis, met its primary and all key secondary endpoints. RTTNews

01:01AM EDT Regeneron : Dupixent Significantly Reduced Itch At 12 Weeks RTTNews

12:59AM EDT Skin Lesions in Phase 3 Trial for Prurigo Nodularis, Demonstrating the Role of Type 2 Inflammation in this Disease PR Newswire

Oct 21, 2021

12:11PM EDT The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO Benzinga

12:11PM EDT Regeneron, Sanofi Report FDA Expands Approval Of Dupixent To Include Children 6-11 Years With Moderate-To-Severe Asthma Benzinga

12:11PM EDT Regeneron Reports FDA Expands Approval Of Dupixent To Include Children 6-11 Years With Moderate-To-Severe Asthma Benzinga

Oct 20, 2021

05:29PM EDT FDA Expands Approval of Dupixent(r) (dupilumab) to Include Children Aged 6 to PR Newswire

Oct 18, 2021

09:17AM EDT Benzinga Pro's Top 5 Stocks To Watch For Monday, Oct. 18, 2021: COIN, REGN, CLAR, ENFN, PTLO Benzinga

07:34AM EDT The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs Benzinga

Oct 14, 2021

10:28AM EDT Why Regeneron Shares Are Rising Today Benzinga

07:46AM EDT Regeneron Pharma: FDA To Review BLA For REGEN-COV Antibody RTTNews

07:26AM EDT Regeneron: FDA Accepts For Priority Review BLA For REGEN-COV To Treat Prophylaxis Of COVID-19 RTTNews

07:23AM EDT Regeneron Pharmaceuticals Announces FDA Accepts REGEN-COV For Priority Review For Treatment And Prophylaxis Of COVID-19 Benzinga

07:22AM EDT FDA Accepts REGEN-COV(r) (casirivimab and imdevimab) for Priority Review for PR Newswire

Oct 12, 2021

12:22PM EDT Expert Ratings For Regeneron Pharmaceuticals Benzinga

08:43AM EDT Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Lowers Price Target to $571 Benzinga

Oct 11, 2021

04:16PM EDT Regeneron to Report Third Quarter 2021 Financial and Operating Results and Host PR Newswire

01:33PM EDT AstraZeneca's COVID-19 Therapy Hits Goal In Phase 3 Trial Benzinga

Oct 4, 2021

10:21AM EDT Tesla and Merck Give Investors Some Hope Benzinga

Oct 1, 2021

02:29PM EDT Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates Benzinga

Sep 30, 2021

07:15AM EDT Regeneron-Roche Post Encouraging New Data For COVID-19 Antibody Cocktail Benzinga

01:41AM EDT Regeneron Pharmaceuticals Inc. (REGN) said that a trial assessing investigational REGEN-COV (casirivimab and imdevimab) in patients hospitalized with COVID-19 met its primary endpoint. RTTNews

01:03AM EDT Regeneron Pharma : New REGEN-COV Data Show Supportive Results In Patients Hospitalized With COVID-19 RTTNews

01:00AM EDT New REGEN-COV(tm) (casirivimab and imdevimab) Data Show Supportive Results in PR Newswire

Sep 29, 2021

05:01PM EDT New England Journal of Medicine Publishes Phase 3 Trial Results for REGEN-COV (casirivimab and imdevimab) to Treat COVID-19 Benzinga

05:00PM EDT New England Journal of Medicine Publishes Positive Phase 3 Trial Results for PR Newswire

Sep 28, 2021

10:19AM EDT Graybug Vision Posts Six-Month Extension GB-102 Data Of Wet AMD Trial Benzinga

08:18AM EDT The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive Benzinga

08:16AM EDT The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK To Develop Long-Acting HIV Treatments Benzinga

07:50AM EDT Regeneron Pharmaceuticals, Inc. (REGN) on Tuesday said its supplemental biologics license application for Libtayo for the treatment of patients with advanced cervical cancer has been accepted by the Food and Drug Administration for priority review. RTTNews

07:05AM EDT Regeneron Pharma: FDA Accepts For Priority Review The SBLA For PD-1 Inhibitor Libtayo For Advanced Cervical Cancer RTTNews

07:03AM EDT Regeneron Pharmaceuticals Announces FDA Has Accepted Libtayo sBLA For Priority Review Benzinga

07:01AM EDT FDA Accepts Libtayo(r) (cemiplimab-rwlc) for Priority Review for Advanced PR Newswire

Sep 27, 2021

04:00PM EDT Glaxo - Vir Biotech's COVID Treatment Approved In Japan Benzinga

Sep 24, 2021

01:19PM EDT WHO Backs Regeneron COVID-19 Antibody Cocktail As It Calls For Equal Access Benzinga

Sep 21, 2021

01:04AM EDT Regeneron Pharma, Sanofi Present New Dupixent Analyses In Patients With Moderate-to-severe Atopic Dermatitis RTTNews

12:59AM EDT New Dupixent(r) (dupilumab) Data in Patients as Young as Six Years Old With PR Newswire

Sep 20, 2021

06:45AM EDT Sanofi, Regeneron, Share Competitive Libtayo Survival Data in 1L NSCLC Benzinga

06:45AM EDT Regeneron Pharmaceuticals And Sanofi On Sunday Announced Phase 3 Results For A Libtayo Combination Treatment; Co. Reported 'Phase 3 trial met its primary and key secondary endpoints' Benzinga

Sep 19, 2021

12:03PM EDT Regeneron Pharma And Sanofi Announce Phase 3 Results For Libtayo Combination Treatment Meets Endpoints RTTNews

11:30AM EDT First-line Treatment Combination Significantly Improved Overall Survival in Patients with Advanced NSCLC PR Newswire

Sep 15, 2021

12:13PM EDT Analyst Ratings For Regeneron Pharmaceuticals Benzinga

10:35AM EDT Breaking Down The Inflation Numbers Draws Attention To Oil Prices Benzinga

08:27AM EDT 10 Biggest Price Target Changes For Wednesday Benzinga

08:01AM EDT After Regeneron, US Government Orders Additional COVID-19 Therapy From Eli Lilly Benzinga

07:57AM EDT After Regeneron, US Govt. Orders For Additional COVID-19 Therapy From Eli Lilly Benzinga

07:54AM EDT U.S. Govt Calls For Additional Doses Of Regeneron's COVID-19 Antibody Therapy Benzinga

07:38AM EDT The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs Benzinga

06:11AM EDT HC Wainwright & Co. Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $831 Benzinga

Sep 14, 2021

11:31PM EDT Regeneron Pharmaceuticals Inc. (REGN) said that it will supply an additional 1.4 million 1,200 mg doses of REGEN-COV (casirivimab and imdevimab) antibody cocktail to the U.S. government by January 31, 2022, at a cost of $2,100 per dose. RTTNews

05:44PM EDT Regeneron Announced New U.S. Government Agreement to Purchase 1.4M Additional Doses of REGEN-COV Antibody Cocktail @$2,100/Dose Benzinga

05:34PM EDT Regeneron Announces New U.S. Government Agreement to Purchase Additional Doses PR Newswire

Sep 8, 2021

04:06PM EDT Regeneron Announces Investor Conference Presentations PR Newswire

Sep 7, 2021

12:43PM EDT Analyst Ratings For Regeneron Pharmaceuticals Benzinga

08:21AM EDT Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $606 Benzinga

Sep 2, 2021

08:20AM EDT The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab Benzinga

Sep 1, 2021

07:32AM EDT The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering Benzinga

Aug 31, 2021

08:15AM EDT The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical Benzinga

Aug 30, 2021

03:55PM EDT Can COVID-19 Antibody Treatment Help In High-Risk Cases? Mayo Clinic, nference Study Shows Potential Benzinga

10:59AM EDT Pfizer's Abrocitinib Beats Dupixent Late-stage Eczema Trial Benzinga

06:59AM EDT Dupixent Becomes First Biologic To Show Benefit In Infant Patients With Atopic Dermatitis Benzinga

01:18AM EDT Regeneron Pharmaceuticals Inc. (REGN) and Sanofi (SNYNF, SNY) said Monday that a pivotal phase 3 trial, which evaluated Dupixent or dupilumab to treat moderate-to-severe atopic dermatitis in children aged 6 months to 5 years, met its primary and all secondary endpoints. RTTNews

01:02AM EDT Regeneron Pharma, Sanofi Announce Phase 3 Results Of Dupixent Meets All Primary And Secondary Endpoints RTTNews

12:59AM EDT Becoming First Biologic Medicine to Significantly Reduce Signs and Symptoms of Moderate-to-severe Atopic Dermatitis in Children as Young as 6 Months PR Newswire

Aug 27, 2021

07:35AM EDT The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration Benzinga

Aug 24, 2021

02:03PM EDT Fauci Says Monoclonal Antibody COVID-19 Treatments Is Being Under-Utilized, Recommends Utilizing It To Fullest Benzinga

12:57PM EDT Regeneron Touts Mid-Stage Win For Higher Dose Of Eylea In Age-related Macular Degeneration Benzinga

08:09AM EDT The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal Benzinga

07:05AM EDT Regeneron Announces Topline Phase 2 Data Of High-Dose aflibercept In Wet Age-related Macular Degeneration Benzinga

07:03AM EDT Regeneron Announces Encouraging Topline Phase 2 Data Of High-dose Aflibercept In Wet Age-related Macular Degeneration RTTNews

07:01AM EDT Regeneron Announces Encouraging Topline Phase 2 Data of High-dose aflibercept PR Newswire

Aug 23, 2021

11:38AM EDT Return on Capital Employed Insights for Regeneron Pharmaceuticals Benzinga

Aug 20, 2021

09:47AM EDT UK Approves Regeneron - Roche's COVID-19 Antibody Cocktail Benzinga

07:45AM EDT The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data Benzinga

07:03AM EDT UK Authorizes Regeneron Pharma Antibody Cocktail To Prevent And Treat Acute COVID-19 Infection RTTNews

07:01AM EDT Regeneron Reports UK Authorized Its Antibody Cocktail To Prevent, Treat Acute COVID-19 Infection Benzinga

07:01AM EDT UK Authorizes Regeneron Antibody Cocktail to Prevent and Treat Acute COVID-19 PR Newswire

Aug 19, 2021

11:47AM EDT Regeneron Granted FDA Orphan Drug Designation For 'Treatment of stage IA2 to stage IV cervical cancer' Benzinga

10:57AM EDT The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck Benzinga

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

07:06AM EDT Regeneron Says Its Antibody-Drug Shipments Rose Ninefold Last Week Vs. Month Earlier Benzinga

Aug 17, 2021

06:17AM EDT Novartis Shares Two Year Beovu Data From Diabetic Macular Edema Studies Benzinga

Aug 6, 2021

10:09AM EDT Ocular Therapeutix, Regeneron Cull Aflibercept Agreement For Retinal Diseases Benzinga

09:27AM EDT Oppenheimer Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $825 Benzinga

09:10AM EDT Barclays Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $705 Benzinga

08:07AM EDT SVB Leerink Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $725 Benzinga

Aug 5, 2021

04:26PM EDT Ocular Therapeutix Announces Termination Of Collaboration With Regeneron To Develop A Sustained-Release Formulation Of Aflibercept For The Treatment Of Wet AMD And Other Serious Retinal Diseases Benzinga

12:48PM EDT Regeneron Pharmaceuticals Says In June 2021 Received Civil Investigative Demand From U.S. Department Of Justice Pursuant To Federal False Claims Act Benzinga

10:52AM EDT Delta, Lambda COVID Variants Still Weighing On Market Despite Positive Earnings Reports Benzinga

08:49AM EDT Daimler Truck AG and U.S.-based engine manufacturer Cummins Inc. (CMI) announced a global strategic partnership for medium-duty engines. RTTNews

07:19AM EDT Regeneron Pharmaceuticals: Q2 Earnings Insights Benzinga

06:37AM EDT Regeneron Pharmaceuticals (REGN) revealed a profit for its second quarter that advanced from the same period last year. RTTNews

06:34AM EDT UPDATE: Regeneron Cuts FY21 Guidance: R&D Spending From $2.7B-$2.85B To $2.65B-$2.75B Benzinga

06:34AM EDT Regeneron Cuts Guidance Benzinga

06:33AM EDT Regeneron Pharmaceuticals Q2 Adj. EPS $25.80 Beats $17.69 Estimate, Sales $5.14B Beat $3.89B Estimate Benzinga

06:32AM EDT Regeneron Q2 Revenues Increase 163% To $5.14 Bln RTTNews

06:31AM EDT Regeneron Reports Second Quarter 2021 Financial and Operating Results PR Newswire

06:19AM EDT Regeneron Pharma And Sanofi: Phase 3 Trial Of Libtayo Combined With Chemotherapy Stopped Early RTTNews

06:08AM EDT Regeneron Says Phase 3 Trial Of Libtayo With Chemotherapy Was Stopped Early After Meeting Overall Survival Primary Endpoint Benzinga

06:01AM EDT Stopped Early Due to Significant Improvement in Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer PR Newswire

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

Aug 4, 2021

05:32PM EDT New England Journal of Medicine Publishes Phase 3 Trial Results for REGEN-COV (casirivimab and imdevimab) to Prevent SARS-CoV-2 Infection Benzinga

05:06PM EDT New England Journal of Medicine Publishes Positive Phase 3 Trial Results for PR Newswire

Aug 3, 2021

07:02AM EDT Regeneron Announces the 2021 Winners of the Regeneron Prize for Creative PR Newswire

Aug 2, 2021

07:51AM EDT 10 Biggest Price Target Changes For Monday Benzinga

06:09AM EDT HC Wainwright & Co. Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $741 Benzinga

06:03AM EDT FDA Approves Regeneron - Roche's COVID-19 Antibody Cocktail For Post-Exposure Prophylaxis Benzinga

Jul 30, 2021

02:24PM EDT Regeneron Pharma Announces FDA Expands Authorized Use Of REGEN-COV RTTNews

01:45PM EDT FDA Expands Authorized Use of REGEN-COV(tm) (casirivimab and imdevimab) PR Newswire

01:45PM EDT Regeneron Pharmaceuticals Says FDA Expands Authorized Use Of REG-COV Benzinga

Jul 29, 2021

08:18AM EDT The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs Benzinga

07:06AM EDT Regeneron - Sanofi's Dupixent Improves Itch, Hives In Inflammatory Skin Disease Patients Benzinga

01:28AM EDT Regeneron Pharmaceuticals Inc. (REGN) and Sanofi, on Thursday, announced that a pivotal Phase 3 trial evaluating Dupixent in patients with moderate-to-severe chronic spontaneous urticaria or CSU met its primary and all key secondary endpoints at 24 weeks. RTTNews

01:03AM EDT Regeneron, Sanofi: Phase 3 Trial On Dupixent In Patients With Chronic Spontaneous Urticaria Met Endpoints At 24 Weeks RTTNews

12:59AM EDT Chronic Spontaneous Urticaria, a Step Forward in Demonstrating the Role of Type 2 Inflammation in These Patients PR Newswire

Jul 27, 2021

11:13AM EDT The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts Benzinga

11:13AM EDT Regeneron, AstraZeneca Report Research, Development, Commercialization Deal For New Small Molecule Medicines For Obesity Benzinga

Jul 22, 2021

01:22PM EDT Sanofi-Regeneron's COPD Drug Fails In Mid-Stage Trial, But Shows Potential Benefit In Subgroup of Former Smokers Benzinga

Jul 20, 2021

05:57AM EDT Regeneron Announced Japan Approved Antibody Cocktail (casirivimab and imdevimab) for the Treatment of Mild to Moderate COVID-19 Benzinga

01:14AM EDT Japan's Ministry of Health, Labour and Welfare has approved Regeneron Pharmaceuticals Inc.'s (REGN) casirivimab and imdevimab antibody cocktail to treat patients with mild to moderate COVID-19. RTTNews

01:00AM EDT Japan Becomes First Country to Approve Regeneron Antibody Cocktail (casirivimab PR Newswire

Jul 16, 2021

12:32PM EDT Governor Cuomo Backs Regeneron's $1.8B Expansion Plans In Westchester County Benzinga